Showing 1911-1920 of 3038 results for "".
- Novartis Implementing Programs to Assist Optometrists During COVID-19https://modernod.com/news/novartis-implementing-programs-to-assist-optometrists-during-covid-19/2477609/Novartis announced that it is implementing the following to ensure optometrists are well-equipped to provide care for patients during the COVID-19 pandemic: Strengthening the online, self-service sample website –
- Small Business Rescue Loan Program Is Now Out of Moneyhttps://modernod.com/news/small-business-rescue-loan-program-is-now-out-of-money/2477598/The Small Business Administration’s rescue loan program hit its $349 billion limit on Thursday and is now out of money as the nation’s top Republicans and Democrats struggle to agree on how to restore its funds, according to a CNBC
- Call for Nominations Issued for the 2020 Bonnie Strickland Champion for Children’s Vision Awardhttps://modernod.com/news/call-for-nominations-issued-for-the-2020-bonnie-strickland-champion-for-childrens-vision-award/2477595/The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH) has issued the call for nominations for the sixth annual “Bonnie Strickland Champion for Children’
- Novavax Accelerates Initiation of COVID-19 Vaccine Trial to Mid-Mayhttps://modernod.com/news/novavax-accelerates-initiation-of-covid-19-vaccine-trial-to-mid-may/2477554/Novavax announced it has identified a coronavirus vaccine candidate, NVX-CoV2373, a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavax’ proprietary Matrix-M adjuvant will be incorporated w
- Incyte, Novartis to Evaluate JAK Inhibitor Ruxolitinib for Severe COVID-19 Patientshttps://modernod.com/news/incyte-novartis-to-evaluate-jak-inhibitor-ruxolitinib-for-severe-covid-19-patients/2477527/Incyte and Novartis announced that the companies plan to initiate a phase 3 collaborative study to assess ruxolitinib plus standard-of-care, versus standard care alone, in patients suffering from COVID-19-associated cytokine storm. The clinical trial will be sponsored by Incyte in the US, where t
- SightGlass Vision Reports Positive Interim Data From Pivotal Clinical Trial of Novel Eyeglasses for Myopia Management in Childrenhttps://modernod.com/news/sightglass-vision-reports-positive-interim-data-from-pivotal-clinical-trial-of-novel-eyeglasses-for-myopia-management-in-children/2477515/SightGlass Vision announced topline results from a planned 12-month interim analysis of the company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Data from the Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety
- Tatsuya Kaihara Appointed CEO of Santen Inc. and Head of North America Business of Santen Pharmaceuticalhttps://modernod.com/news/tatsuya-kaihara-appointed-ceo-of-santen-inc-and-head-of-north-america-business-of-santen-pharmaceutical/2477510/Santen announced the appointment of Tatsuya Kaihara as Corporate Officer and Head of North America Business of Santen Pharmaceutical. As of April 1, he is also appointed as CEO of Santen Inc. and he will lead the company’s North America business and report to Shigeo Taniuchi, P
- Mallinckrodt and Novoteris Receive Clearance from Health Canada to Start Pilot Trial of Inhaled Nitric Oxide Therapy for COVID-19https://modernod.com/news/mallinckrodt-and-novoteris-receive-clearance-from-health-canada-to-start-pilot-trial-of-inhaled-nitric-oxide-therapy-for-covid-19/2477506/Mallinckrodt and Novoteris announced that the Therapeutic Products Directorate of Health Canada has cleared the companies’ joint pilot clinical trial, entitled “Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung
- Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minuteshttps://modernod.com/news/abbott-launches-molecular-point-of-care-test-to-detect-novel-coronavirus-in-as-little-as-five-minutes/2477479/Abbott announced that the FDA has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as 5 minutes and negative results in 13 minutes, according to a company new
- NovaBay Pharmaceuticals Announces the Availability of KN95 Disposable Masks on Avenova.comhttps://modernod.com/news/novabay-pharmaceuticals-announces-the-availability-of-kn95-disposable-masks-on-avenova-com/2477457/NovaBay Pharmaceuticals announced the availability of KN95 disposable air filter masks on the company’s website